Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
December 2016, Vol 7, No 11
Economics & Value
First National Study: Geographic Socioeconomic Disparities Mirror Substantial Gaps in Survival in Children with AML
Chase Doyle
Real-World Healthcare Utilization and Costs Support Broader Use of CAR T-Cell Therapy
Phoebe Starr
Value-Based Care Management Medicare Program Changes for 2020 and Beyond
Joseph S. Bailes, MD
,
Gena Cook
View More Articles
Personalized Medicine
Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive
Nadia Jaber
Liquid Biopsies on the Horizon for Children With Solid Cancers
Ella Ben-Ari
Recent Developments in Genomic-Driven Therapies for Cholangiocarcinoma
View More Articles
Value in Oncology
NCCN Panel Debates Cancer Care in Value-Based Healthcare Models
Wayne Kuznar
FDA Implements New Steps to Encourage Generic Drug Competition, Expand Patients’ Access to Inexpensive Medicines
Eileen Koutnik-Fotopoulos
Rapid Adoption of Oncology Drugs Improves Survival
Chase Doyle
View More Articles
FDA Approvals, News & Updates
Fruzaqla FDA Approved for Relapsed Metastatic Colorectal Cancer
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Metastatic or Recurrent Nasopharyngeal Carcinoma
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of GEJ Adenocarcinoma
View More Articles
Emerging Therapies
Zanidatamab Demonstrates Efficacy in Refractory HER2-Amplified Biliary Tract Cancer
Investigational mRNA-Based Vaccine May Offer New Hope for Patients With High-Risk Melanoma
Phoebe Starr
First-Line Mosunetuzumab Safe and Effective in Older Patients with Diffuse Large B-Cell Lymphoma
Chase Doyle
View More Articles
Immunotherapy
Immunotherapy After Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer
Sharon Reynolds
Personalized Vaccine plus Immune Checkpoint Inhibitor a Promising Approach to Cancer
Phoebe Starr
FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer
Yvette Florio Lane
View More Articles
Employers Look to Manage the Benefits of Specialty Pharmacy
By
Wayne Kuznar
Employers’ Perspective
,
Specialty Pharmacy
,
Value Peer-spectives
December 2016, Vol 7, No 11
Washington, DC—Employers recognize that oncology care is expensive, and they are shifting their focus on cost management. As such, employers are seeking approaches to determine which drugs and health plan designs will help them manage pharmacy and medical costs to improve patient outcomes, said F. Randy Vogenberg, PhD, RPh, Partner, Access Market Intelligence, and National Institute of Collaborative Healthcare, Greenville, SC, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Navigating Patient Assistance Programs
By
Jessica Miller
Patient Navigation
,
Patient Support Services
,
Policies & Guidelines
December 2016, Vol 7, No 11
Washington, DC—In the past 6 years, more than $4 billion in charitable assistance has been dedicated to patients in need. In 2015 alone, the Patient Access Network (PAN) Foundation provided $950 million in cancer care support. The only people with deep enough pockets to support this type of assistance are drug manufacturers, adding to an already complicated regulatory environment for charitable assistance programs, said Daniel J. Klein, President and Chief Executive Officer, PAN Foundation, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Cost, Access, and Delivery Challenge New Oncology Drug Options
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—Although significant advancements in oncology research, development, and treatment have improved cancer care, they have been accompanied by rising drug costs, and differences in drug availability and delivery worldwide. These trends will continue into 2020, according to Douglas Long, Vice President, Industry Relations, IMS Health.
Read Article
Value-Based Oncology Management and Outcomes-Based Contracting
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—An innovative, value-based approach to managing the cost of oncology care moves away from drug-spending volume toward the appropriate use and quality of drug therapy, said Alan Lotvin, MD, Executive Vice President, Specialty Pharmacy, CVS Health, Woonsocket, RI, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Cost-Savings Measures Will Dot the Oncology Landscape
By
Wayne Kuznar
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—Risk arrangements with physicians and transferring the costs of care onto patients are expected to increase in 2017, as payers attempt to manage high-cost disease states, such as cancer care, said Marie A. Hollowell, Senior Manager, Syndicated Research, Zitter Health Insights, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
ASCO CEO Addresses Quest for Value in Cancer Care
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—Treatments and technologies for cancer care are becoming increasingly expensive, fueling a need to define and improve value. As a result, the American Society of Clinical Oncology (ASCO) is refining its value framework that supports informed shared decision-making between doctors and patients and considers the clinical benefit, cost, and toxicity of cancer treatments. The goal is to have a tool that can customize information for each patient.
Read Article
Quality Measures Are Key to Supporting Drug Value
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—An opportunity for value enhancement from the drug manufacturer’s perspective includes the improved use of data to meet the needs of stakeholders, especially the patient. Data that are generated should support the value of the manufacturer’s therapies in light of newly established value-based models, which often rely on quality metrics, for example, that are not obvious from clinical trials. Finally, wraparound services can add to a drug’s value and help to distinguish it from a competitor’s drug.
Read Article
Cancer Treatment Costs and Trends Beckon Risk-Sharing Future
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—Oncology care is facing rising costs that will demand a transformation from a fee-for-service reimbursement model to a value-based, shared-risk incentive plan for Medicare and commercial insurance plans. Bruce Pyenson, FSA, MAAA, Principal and Consulting Actuary, Milliman, New York, NY, provided an overview of the cost trends of cancer treatment costs at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
PhRMA’s Perspective on Value-Driven Healthcare
By
Wayne Kuznar
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—Payers are increasingly evaluating methods to manage oncology care costs in the new value-driven healthcare system. These methods include improved quality measurement and value-assessment tools, the appropriate use of drugs, and value-based contracts with health plans.
Read Article
FDA News - December 2016
FDA Approvals, News & Updates
December 2016, Vol 7, No 11
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma